Ferroptosis in Intrahepatic Cholangiocarcinoma:
GPX4
IDH1105GGT single nucleotide polymorphism
STAT3
ferroptosis
intrahepatic cholangiocarcinoma
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
02
2022
accepted:
21
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis and often demonstrates an anti-apoptotic landscape, which is a key step to chemotherapy resistance. Isocitrate dehydrogenase 1 or 2 ( We enrolled 112 patients who underwent hepatic resection or diagnostic liver biopsy for ICC. Immunostaining for transferrin-receptor 1 and GPX4, and Pearls' stain for iron deposits were performed to evaluate ferroptosis activation. Immunostaining for STAT3 was performed to study pro-inflammatory and anti-apoptotic landscape. Main GPX4 overexpression was seen in 79.5% of cases and related to poor histological prognostic factors (grading and perineural and vascular invasion; Our study demonstrates for the first time that in most inflammatory ICCs ferroptosis is not active, and its triggering is related to
Identifiants
pubmed: 35872783
doi: 10.3389/fmed.2022.886229
pmc: PMC9304620
doi:
Types de publication
Journal Article
Langues
eng
Pagination
886229Informations de copyright
Copyright © 2022 Sarcognato, Sacchi, Fabris, Zanus, Gringeri, Niero, Gallina and Guido.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Cancer. 2014 Nov;14(11):736-46
pubmed: 25342631
Oncologist. 2012;17(1):72-9
pubmed: 22180306
Oncotarget. 2017 Mar 28;8(13):22145-22165
pubmed: 27888618
Front Cell Dev Biol. 2021 Jun 09;9:629150
pubmed: 34178977
Blood. 2011 Oct 27;118(17):4561-6
pubmed: 21873548
Biochem Biophys Res Commun. 2010 Mar 12;393(3):555-9
pubmed: 20171178
Cancers (Basel). 2021 Oct 15;13(20):
pubmed: 34680318
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Eur J Endocrinol. 2010 Nov;163(5):747-55
pubmed: 20702649
Sci Rep. 2018 Mar 13;8(1):4459
pubmed: 29535392
Hepatology. 2019 Apr;69(4):1803-1815
pubmed: 30251463
Pathologica. 2021 Jun;113(3):158-169
pubmed: 34294934
Int J Mol Sci. 2017 Jan 13;18(1):
pubmed: 28098760
Discov Med. 2019 Nov-Dec;28(155):255-265
pubmed: 32053766
Cell Rep. 2017 Jun 27;19(13):2878-2880
pubmed: 28658632
Surg Clin North Am. 2020 Jun;100(3):535-549
pubmed: 32402299
Mol Interv. 2011 Feb;11(1):18-26
pubmed: 21441118
Gastroenterology. 2013 Apr;144(4):829-40
pubmed: 23295441
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncotarget. 2015 Sep 22;6(28):26052-64
pubmed: 26296968
Surg Oncol Clin N Am. 2019 Oct;28(4):587-599
pubmed: 31472907
Science. 1994 Jun 3;264(5164):1415-21
pubmed: 8197455
Cancer. 2013 Feb 15;119(4):806-13
pubmed: 23184331
Clin Cancer Res. 2016 Jan 15;22(2):291-300
pubmed: 26405193
Cell Death Dis. 2019 Oct 7;10(10):755
pubmed: 31591388
Virchows Arch. 2019 Jan;474(1):29-37
pubmed: 30377796
Pathol Res Pract. 2021 May;221:153445
pubmed: 33887545
J Cell Mol Med. 2019 Aug;23(8):4900-4912
pubmed: 31232522
J Clin Oncol. 2010 May 10;28(14):2356-64
pubmed: 20368538